The market for Breast Lesion Localization Methods will grow at a healthy CAGR of 13.57%, from a value of $966.56 million in 2021 to $3038 million by 2030.
These treatments are used to find breast abnormalities like tumors or lumps. The average age of the patient, the length of the treatment, its success, the expense of the operation, its safety, and its ease of use are all important considerations for the surgeon when selecting the best localization technique. All throughout the world, several Transcatheter Aortic Valve Replacement are used to find lumps or cancers in the breast. Technologies for localizing breast lesions include radioisotope localization, wire localization radiology, agreed localization, savi scout localization, RFID breast localization, preoperative radioactive seed localization, radio-guided occult lesion localization, magnetic seed localization, and chemotherapy.
Market Dynamics
DRIVERS:
- Numerous factors, such as the rising prevalence of breast enlargements among women and the increasing use of contraceptive pills, contribute to the development of breast lesions. Additionally, the market is expanding due to the increased occurrence of breast illnesses such as breast cancer and cysts.
- The rising incidence of breast cancer, the expansion of breast cancer surgeries, expanded government & non-government payment schemes, and rising public awareness of breast cancer diagnoses are all factors contributing to the market’s rise.
- Worldwide, there are more incidences of breast cancer, which increases the need for early detection. The most frequent cancer in women is breast cancer, and rising rates are expected to drive market expansion.
RESTRAINTS:
The exorbitant expenses of cutting-edge gadgets, the strict regulations governing product clearance procedures, and a dearth of oncologists and qualified specialists in many emerging countries are all impeding the global market. Additionally, the regulatory issues with breast localization and defective products may restrict market expansion.
OPPORTUNITIES
There are ample opportunities for market participants as a result of aggressive government investment in the development and modernization of healthcare infrastructure. Additionally, the market has favourable growth prospects due to ongoing technological developments and a growing public understanding of breast cancer detection.
By Techniques
- Wire Localization
- Electromagnetic localization
- Radioisotope localization
- Magnetic localization
- Others
By Usage
- Tumor identification
- Sentinel lymph node identification
- Lumpectomy
By End-User
- Hospitals
- Oncology Clinics
- Diagnostics Centres
- Others
Geography
North America
- USA
- Mexico
- Canada
- Rest of N.A.
Europe
- Suomi (Finland)
- Hungary
- Germany
- U.K.
- France
- Switzerland
- Turkey
- Netherlands
- Rest of Europe
Asia Pacific
- Japan
- China
- South Korea
- India
- Australia
- Rest of APAC
LAMEA
- Argentina
- Brazil
- Saudi Arabia
- Uruguay
- Rest of L.A.M.E.A.
According to the Technique segment, the Wire Localization market segment accounted for the majority of the share in 2021. It is a result of its precision in procedures that localize diseased tissue. The Radioisotope market segment is projected to expand significantly over the anticipated period because it is one of the most recent techniques for preoperative localization of non-palpable, & suspicious lesions. It is also a widely utilized, safe, and effective procedure. Although it is not felt throughout a clinical breast exam, a non-palpable mammary mass can be found via ultrasonography, mammography, or MRI. Twenty to thirty percent of people with non-palpable breast lumps develop breast nodules into cancer, according to the United States Medical Association and National Institute of Health.
With a share of the market of $ 43.1 million in 2020 for all breast lesion localization procedures, the ‘Tumour Identification’ market category will rule the industry. Due to the growing adoption of SLNB as a primary diagnostic method for breast cancer staging, it is anticipated that the identification of sentinel lymph nodes will grow at the fastest rate during the course of the projected period. In comparison to earlier breast cancer staging procedures, it is also more sensitive and causes less morbidity.
Amongst the end-user market segments, the Hospitals segment is anticipated to generate USD 596.2 million in revenue between 2021 and 2028. The prevalence of skilled professionals, rising breast cancer occurrence, and growing adoption of new Transcatheter Aortic Valve Replacement are all contributing to the growth. Oncology clinics are the sector that is expanding at the greatest rate, with a consistent CAGR of 12.13 percent.
Due to the surge in breast cancer cases, the growth of breast cancer operations, and the increased awareness of breast cancer early detection, North America is projected to result in a sizeable portion of the global market. In addition, Asia Pacific is expected to expand at the fastest rate because of rising disposable income levels, significant unmet healthcare needs, and elevated patient awareness of early diagnosis.
Key Companies
- Mermaid Medical A/SArgon Medical Devices
- Becton, Dickinson, and Company
- IZI Medical Products
- Sirius Medical B.V.
- Tsunami Medical
- R. Bard
- Molli Surgical
- SOMATEX Medical Technologies GmbH
- Endomagnetics
- Cianna Medical
- Laurane Medical
- BPB Medica
- CP Medical
- Cook Medical
- Cianna Medical